A viral vector prime and protein boost vaccine regimen elicits higher binding antibody titers than a homologous viral vector prime-boost regimen
Open Access
- 17 September 2025
- journal article
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 9 (10)
Abstract
(SARS-CoV-2) has infected a large fraction of the human population. Currently, most individuals have developed immunity either through vaccination or natural infection. Despite this, SARS-CoV-2 booster immunizations are still recommended to reduce the risk of reinfections, but there is still limited understanding of how different booster vaccine platforms influence antibody responses. We conducted immunological studies in mice to evaluate the boosting effects of different vaccine platforms on antibody responses. C57BL/6 mice were first primed with an adenovirus serotype 5 (Ad5) vector vaccine expressing the SARS-CoV-2 spike protein. The mice were then boosted with the same Ad5-based vaccine (homologous boosting) or with a protein-based vaccine (heterologous boosting). Interestingly, the heterologous regimen (Ad5 prime/Protein boost) elicited higher binding antibody responses, relative to the homologous regimen (Ad5 prime/Ad5 boost). Similar potentiation of antibody titers was reported when mice were primed with poxvirus or rhabdovirus vectors and then boosted with protein. These findings highlight a potential advantage of protein booster immunizations to potentiate humoral immunity.Keywords
Funding Information
- National Institutes of Health (NIAID R56AI187084)
This publication has 25 references indexed in Scilit:
- A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2Cell, 2020
- An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaquesNature Communications, 2020
- A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challengeNature Communications, 2020
- Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaquesNature, 2020
- TLR4 signaling improves PD-1 blockade therapy during chronic viral infectionPLOS Pathogens, 2019
- Vaccine-elicited CD4 T cells induce immunopathology after chronic LCMV infectionScience, 2015
- Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infectionJournal of Experimental Medicine, 2014
- Alternative Serotype Adenovirus Vaccine Vectors Elicit Memory T Cells with Enhanced Anamnestic Capacity Compared to Ad5 VectorsJournal of Virology, 2013
- Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in ThailandNew England Journal of Medicine, 2009
- Preferential Localization of Effector Memory Cells in Nonlymphoid TissueScience, 2001